CoChat
Sign Up
Cited by 59

The DOI matches its Crossref record.

MMP14 predicts a poor prognosis in patients with colorectal cancer

Cui, Guangfei, Cai, Feng, Ding, Zhanwei, Gao, Ling·2019·Human Pathology
DOI 10.1016/j.humpath.2018.03.030
Open this paper in CoChat — free account

Abstract

Matrix metalloproteinases (MMPs) are involved in most biological processes. Recently, MMP14 was reported to be up-regulated in some types of cancer and to promote cancer cell invasion and metastasis. However, there are few reports on the clinical significance of MMP14 in colorectal cancer (CRC). In this study, MMP14 expression was first investigated in The Cancer Genome Atlas (TCGA) and whole-genome expression microarray (GEO; Accession Number GSE39582) and then validated with our database. Univariate and multivariate analyses were performed to assess the association between prognostic factors and survival outcomes. MMP14 was upregulated at both the transcriptional and protein levels in cancer compared with normal tissues (P < .05), and high MMP14 expression was associated with advanced tumor stage in the 3 study cohorts. In the univariate Cox proportional hazard ratio analysis, MMP14 correlated significantly with prognosis in both the TCGA and GSE39582 databases (P < .05). In the validation cohort, patients with high MMP14 expression had lower 5-year disease-free survival (DFS; hazard ratio [HR] 6.707; 95% confidence interval [CI] 3.184, 14.128; P < .001) and overall survival (OS; HR 10.669; 95% CI 3.828, 29.737; P < .001) than those with low MMP14 expression. Multivariate survival analysis showed that MMP14 was an independent prognostic marker for both DFS (HR 5.776; 95% CI 2.719, 12.270; P < .001) and OS (HR 8.971; 95% CI 3.199, 25.156; P < .001). Clearly, MMP14 plays an i…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.humpath.2018.03.030

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 · DOI · Paper page
  2. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 · DOI
  3. Urosevic, 2014, Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH, Nature Cell Biol, 16, 685, 10.1038/ncb2977 · DOI
  4. Chuang, 2017, Aminopeptidase a initiates tumorigenesis and enhances tumor cell stemness via TWIST1 upregulation in colorectal cancer, Oncotarget, 8, 21266, 10.18632/oncotarget.15072 · DOI
  5. Eschrich, 2005, Molecular staging for survival prediction of colorectal cancer patients, J Clin Oncol, 23, 3526, 10.1200/JCO.2005.00.695 · DOI
  6. McLeod, 1999, Tumour markers of prognosis in colorectal cancer, Br J Cancer, 79, 191, 10.1038/sj.bjc.6690033 · DOI
  7. Li, 2015, Overexpression of forkhead box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial–mesenchymal transition, Am J Cancer Res, 5, 2022
  8. Hornebeck, 2002, Matrix-directed regulation of pericellular proteolysis and tumor progression, Semin Cancer Biol, 12, 231, 10.1016/S1044-579X(02)00026-3 · DOI
  9. Rempe, 2016, Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers, J Cerebr Blood Flow Metab, 36, 1481, 10.1177/0271678X16655551 · DOI · Paper page
  10. Baker, 2002, Metalloproteinase inhibitors: biological actions and therapeutic opportunities, J Cell Sci, 115, 3719, 10.1242/jcs.00063 · DOI
  11. Pahwa, 2014, Monitoring and inhibiting MT1-MMP during cancer initiation and progression, Cancer, 6, 416, 10.3390/cancers6010416 · DOI
  12. Dong, 2015, Increased expression of MMP14 correlates with the poor prognosis of Chinese patients with gastric cancer, Gene, 563, 29, 10.1016/j.gene.2015.03.003 · DOI
  13. Itoh, 2006, MT1-MMP: a potent modifier of pericellular microenvironment, J Cell Physiol, 206, 1, 10.1002/jcp.20431 · DOI
  14. Wang, 2017, RNA sequencing analysis reveals protective role of Kruppel-like factor 3 in colorectal cancer, Oncotarget, 8, 21984, 10.18632/oncotarget.15766 · DOI
  15. Sato, 1994, A matrix metalloproteinase expressed on the surface of invasive tumour cells, Nature, 370, 61, 10.1038/370061a0 · DOI
  16. Hui, 2015, Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis, Int J Clin Exp Pathol, 8, 3556
  17. Lehti, 2005, An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature, Genes Dev, 19, 979, 10.1101/gad.1294605 · DOI
  18. Jiang, 2006, Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells, Int J Mol Med, 17, 583
  19. Sabeh, 2004, Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP, J Cell Biol, 167, 769, 10.1083/jcb.200408028 · DOI
  20. Ager EI, Kozin SV, Kirkpatrick ND, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst 2015;107:djv017. · DOI
  21. Zuo, 2015, MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and snail, Cell Death Dis, 6
  22. Jia LF, Wei SB, Mitchelson K, et al. miR-34a inhibits migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14. PloS One 2014;9:e108435. · DOI
  23. Li T, Xie J, Shen C, et al. miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14. PloS One 2014;9:e115577. · DOI

Cited by

Sorted by citations

Metadata

Authors
Cui, G., Cai, F., Ding, Z., & Gao, L.
Venue
Human Pathology
Publisher
Elsevier BV
Published
2019-01
Volume
83
Pages
36-42
ISSN
0046-8177
DOI
10.1016/j.humpath.2018.03.030
Cited by
59
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review